The Translational Research Collaborative for Mental Health - - PowerPoint PPT Presentation

The Translational Research Collaborative for Mental Health

Director, NIHR Biomedical Research Centre at the Maudsley Vice Dean Research, Institute of Psychiatry Psychology and Neuroscience, KCL Professor Matthew Hotopf CBE FMedSci

NIHR TRC-Mental Health

BURDEN UNMATCHED BY RESEARCH FUNDING

Mental health research receives 5.5% of total UK health research spend Amount spent on research per person affected: CANCER: £1,571 MENTAL ILLNESS: £9.75

£9.75 0.3p

For every £1 spent by Government on mental heath research, the general public donates 0.3p. It’s £2.75 for cancer

MQ Landscape Analysis, April 2015

£1571

NIHR TRC-Mental Health

MRC’s strategic priorities for lifelong mental health research

• Employing a lifelong perspective with a focus on children and young

people

• Stratified medicine for mental health research
• Developing new interventions
• The power of data and informatics: population and cohort studies
• Going global
• Prevention of mental illness
• Building capacity and support for the next generation of mental

health researchers

• Building a new UK flagship investment in mental health research

NIHR TRC-Mental Health

DoHSC Framework

Recommendations

• Life course approach
• Patient and Public Involvement
• Mental and Physical Health
• Co-ordination and infrastructure
• Data, informatics and virtual

populations

• Flexible funding
• Emerging interventions and

alternative settings

• Industry engagement
• Regulation ethics and governance
• Capacity building

NIHR TRC-Mental Health

NIHR BRC Funding by disease area

NIHR TRC-Mental Health

Translational Research Collaborative for mental health

Nottingham Bristol C&I/UCL Oxford Cambridge SLaM/KCL Newcastle Manchester Exeter Imperial Southampton

NIHR TRC-Mental Health

Aims

 To form a national network of centres involved in experimental medicine and clinical trials in mental health.  To use this network as a means to accelerate translation of discovery science into clinical practice.  To provide a coherent national presence for industry engagement and collaboration and thereby to increase industry investments in mental health research in England.  To increase the numbers of people with mental disorders recruited into experimental medicine studies and trials.

NIHR TRC-Mental Health

TRC-MH

NIHR TRC-Mental Health

Treatment resistant depression

• Build on several ongoing collaborative trials and mechanistic studies
• n drugs, neuromodulation, psychological and digital interventions

– PAX-BD (NIHR HTA) – MindDep Minocycline (Wellcome) – LQD (Lithium vs antipsychotics in TRD) (HTA) – Theta burst stimulation trial (NIHR EME) – ROSHI2 – group CBT in S. Asian women with postnatal depression (NIHR HTA) – BIODEP (inflammation in TRD) WT and industry

NIHR TRC-Mental Health

CRIS and Clinical Informatics

• CRIS system unlocks EHR data and

capitalizes on digital maturity of mental health notes.

• Developed in Maudsley and

disseminated under D-CRIS to Oxford Cambridge and UCL.

• Multiple linkages including IAPT and

National Pupil Database

• Under Dementia Platform UK

disseminated further as UK-CRIS led by Oxford.

• Now 2.5m+ health records providing

rich, pseudonymised data resource

• UK CRIS sites NHS Trusts in total

selected by proximity to UK Biobank recruitment centres now linked to UKB

NIHR TRC-Mental Health

NIHR Mental Health Bioresource

 Will be established within NIHR BioResource in 2018/19, led by NIHR Maudsley BRC  Aim recruit >20,000 participants in year 1 from multiple sites, with a initial focus on depression and anxiety  Recruitment of NHS Improving Access to Psychological Therapies (IAPT) patients through web portal, with standardised phenotype data and DNA collection  Use of App based e-Mental Health and experimental psychology phenotyping for anxiety and depression  Samples analysed using Affymetrix UK Biobank Axiom Array, with possibility for further whole genome sequencing

NIHR TRC-Mental Health

Markers of success

 Increase in the number of joint collaborative experimental medicine studies and clinical trials operating between centres  Increase in the scale of industry investment in TRC-adopted studies  Increase scale of charity investment in TRC-adopted studies  Increase the number of participants enrolled in mental health studies involving collaborations between centres.